Deals
Amgen Said to Push for Lower Onyx Price Amid Data Dispute
This article is for subscribers only.
Amgen Inc. is pushing to pay less than the $130 a share it offered this month for Onyx Pharmaceuticals Inc. after failing to obtain requested clinical trial data, said people with knowledge of the matter.
Onyx refused to give Amgen additional data on blood-cancer treatment Kyprolis, said one of the people, who asked not to be named because the process is private. Amgen wanted the information to more accurately value the drug, people familiar with the situation said last week. Onyx doesn’t want to relinquish the data in part because they pertain to individual patients, one person said.